Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.

Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.

Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

Abstract: Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.

Abstract: The presently disclosed subject matter provides compositions and methods comprising improvements of a CRISPR system (e.g. CRISPR associated (Cas) 9 (CRISPR-Cas9, non-Cas9 CRISPR systems). Such compositions may comprise modifications to the H1 promoter region, addition of 5?UTR modifications, different orthologous sequences of the H1 promoter, novel compact bidirectional promoter sequences with both pol II and pol III activity, addition of Kozak consensus sequences, termination sequences, addition of conditional pol II/pol III bidirectional promoter expression, addition of a donor template sequence for correcting mutations, or combinations thereof. Other aspects of the invention relate to modifications to Cas9 through post-transcriptional cell-cycle regulation fusions, engineered partial target sites such that the nuclease can bind without DNA cleavage, auto-regulation sites, and N-terminal modifications to modulate half-life.

Abstract: The present invention relates to compositions and adeno associated viral vectors comprising an optimised HGSNAT nucleic acid sequence of SEQ ID No. 1 or a derivative sequence having at least 77% homology thereof. Uses of such compositions and vectors are also contemplated along with kits of parts for their administration.

Abstract: Synthetic adenoviruses with liver detargeting mutations and expressing an adenovirus type 34 (Ad34) fiber protein, or a chimeric fiber protein with an Ad34 knob domain, are described. The synthetic adenoviruses traffic to sites of tumors. Use of the synthetic adenoviruses for delivering diagnostic or therapeutic transgenes to tumors are also described.

Abstract: Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Abstract: Synthetic adenoviruses with tropism to bone tissue are described. The synthetic adenoviruses include an adenovirus type 11 (Ad11) fiber protein or a chimeric adenovirus fiber protein having an Ad11 knob domain. The synthetic adenoviruses can also include a transgene, such as a reporter gene or a transgene encoding a factor that promotes bone regeneration or repair. Use of the synthetic adenoviruses to target bone tissue and/or to promote bone repair or regeneration is also described.

Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: The invention relates generally to the use of dyes to enhance visualization of tissues and boundaries of openings in tissues during cataract surgery.

Abstract: The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring, typically in the context of therapy, in particular in the context of oncology, to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticle aggregates, wherein: i) the density of each nanoparticle and of each nanoparticle aggregate is at least 7 g/cm3, the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C.

Abstract: The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.

Abstract: This disclosure relates to a system and method for disinfecting a conduit, such as a conduit for use in a continuous positive airway pressure (CPAP) system. An example system according to this disclosure includes a sheath a probe magnetically suspended within the sheath. The probe includes an ultraviolet light source configured to emit ultraviolet light. Further, the probe is spaced-apart from an inner dimension of the sheath to allow a conduit to pass between the probe and the sheath.

Abstract: The present invention relates generally to an ultraviolet sterilization module for sterilizing a fluid using ultraviolet light. More particularly, the present invention relates to an ultraviolet sterilization module, configured such that an increase in amount of ultraviolet irradiation is achieved, thus efficiently sterilizing a fluid inside a light transmission member without requiring an increase in size of the light transmission member.

Abstract: Disclosed is a method of sterilizing an article by sequentially exposing the article under vacuum first to a gaseous conditioning agent for forming radicals and then to a sterilant. The preferred conditioning agent is hydrogen peroxide and the preferred sterilant is ozone. The chamber is initially evacuated to a first vacuum pressure and then sealed for the remainder of the sterilization process and during all sterilant injection cycles, without removal of any component of the sterilization atmosphere, which means without any measures to reduce the water vapor content. Keeping the chamber sealed and maintaining the conditioning agent and the radicals generated thereby in the chamber for the sterilization with sterilant results in a synergistic increase in the sterilization efficiency and allows for the use of much lower sterilant amounts and sterilization cycle times than would be expected from using the conditioning agent and the sterilant in combination.

Abstract: A sterilization, disinfection, sanitization, or decontamination system having a chamber defining a region, and a generator for creating a free radical effluent with reactive oxygen, nitrogen, and other species and/or a vaporizer. A closed loop circulating system without a free-radical destroyer is provided for supplying the mixture of free radicals from the generator mixed with the hydrogen peroxide solution in the form of the effluent to the chamber. The system is used in sterilizing, disinfecting, sanitizing, or decontaminating items in the chamber or room and, with a wound chamber, in treating wounds on a body. The wound chamber may be designed to maintain separation from wounds being treated. Various embodiments can control moisture to reduce or avoid unwanted condensation. Some embodiments can be incorporated into an appliance having a closed space, such as a washing machine. Some embodiments may include a residual coating device that deposits a bactericidal coating on sterilized items.

Abstract: A germ-reducing pen container including a body having a hollow passageway extending therethrough from an insertion end to a distal end for receiving a pen, the hollow passageway having at least one ultraviolet C light operatively attached thereto, an indicator on an outer surface of the body, and a dispensing mechanism operatively attached at the insertion end for dispensing the pen. A method of reducing germs on a pen, by inserting a pen into a body of a germ-reducing pen container, applying ultraviolet C light to the pen, killing the germs on the pen, indicating that the pen has been cleaned, and dispensing the pen.

Abstract: Systems and methods are disclosed for cleaning and sterilizing fluids and other materials. In one implementation, one or more emitters are submerged within a fluid and emit electromagnetic waves having a variable frequency. The frequency of the electromagnetic waves is swept across a frequency range to neutralize bacteria, viruses, and other pathogens in the fluid. The emitters may be submerged within a fluid reservoir and/or within the interior of an enclosed fluidic path (e.g., a pipe). Solid materials may be sterilized by immersing the solid materials within the fluid of such a fluid reservoir. In another implementation, electromagnetic waves may be applied to one or more wires that are wrapped around an exterior wall of a pipe. The frequency of the electromagnetic waves may be varied across a frequency range, resulting in scale and other materials being cleaned from the interior wall of the pipe.

Abstract: The present disclosure provides advantageous tray and bracket assembly that is configured and adapted to promote modularity and withstand the harsh environment of central sterile processing processes. Modular bracket assembly may be removed and relocated on tray without additional fasteners or components. Tray and bracket assembly may further provide identification features to correctly associate cataloged reusable medical devices to identified trays.

Abstract: Disclosed is a method of producing a deodorant. The method comprises: contacting oxidized cellulose nanofibers having carboxyl groups and containing ions of a first metal in salt form, dispersed in a solvent in the concentration of 0.005% by mass or more and 0.1% by mass or less, with a salt of a second metal other than the first metal to produce metal-containing oxidized cellulose nanofibers. The metal-containing oxidized cellulose nanofibers comprise the oxidized cellulose nanofibers having carboxyl groups and ions of the second metal, the ions of the second metal forming salts with the carboxyl groups of the oxidized cellulose nanofibers, and the metal-containing oxidized cellulose nanofibers have a number-average fiber diameter of 2 nm or more and 100 nm or less, where the second metal is a metal other than sodium.

Abstract: A scent neutralizing unit includes a housing, an odor neutralizing gas emitter, and an active noise canceling system. The odor neutralizing gas emitter is coupled to the housing and is configured to provide an odor neutralizing gas that neutralizes odor particles. The active noise canceling system includes a microphone configured to generate a captured signal representing a noise signal, an acoustic transducer configured to emit audio signals, and a controller operatively coupled to the microphone and the acoustic transducer and configured to receive the captured signal from the microphone. The controller is configured to control the acoustic transducer to emit an anti-noise signal based on the captured signal where the anti-noise signal is configured to attenuate the noise signal.

Abstract: Improved air freshener dispenser for car comprising a rigid air freshener container; a dispensing nozzle longitudinally oriented and coupled to an upper end of the air freshener container such that it emits a dose of air freshener every time the user presses said nozzle downwards; and an absorbing element surrounding an outlet orifice of the dispensing nozzle such that all the air freshener emitted by said nozzle impregnates said absorbing element.

Abstract: A formable orthopedic device having at least one first configuration and at least one second configuration, the second configuration being adapted to provide support to at least one limb, the device being made of a thermoplastic polymeric material selected to have an elastic modulus of at least about 1500 MPa when measured according to ASTM D638, a glass transition temperature (Tg) of between about 65° C. and about 120° C., and elongation to break of at least 75% when measured according to ASTM D638, the device being capable to be formed into the second configuration by heating the device to said Tg.

Abstract: A degradable and absorbable hemostatic fiber material, a preparation method therefor, and a hemostatic fiber article thereof. The carboxylation degree of the hemostatic fiber material is 10-25%, and the polymerization degree of the hemostatic fiber material is 10-250. The hemostatic fiber material comprises fiber filaments, the linear density of the fiber filament being 0.8-4.5 dtex, and the dry strength of the fiber filament being 10-150 cN/tex. The degradable and absorbable hemostatic fiber material has a higher carboxylation degree and a lower polymerization degree, while the strength and completeness of the fiber filament can be well maintained, such that the hemostatic effect is better and the hemostasis is faster. Further, the hemostatic fiber material can be degraded and absorbed, and thus is safer.

Abstract: A new MANUFACTURING PROCESS FOR AN ADHERENT SILICONE HEALING TAPE/PAD/DRESSING OF SPECIFIC SHAPES, for application in the medical area aiming to provide greater results in the healing of keloid scars as a fibroproliferative disorder, since the following specific properties make silicone useful for dressings: safe, low thermal conductivity, low chemical reactivity, low toxicity and rare adverse reactions, as the silicone cannot be absorbed into the body, repels the water and creates a watertight seal, it does not support microbial growth, has high gas permeability, and is adherent to dry skin.

Abstract: A novel therapeutic agent for solid cancer capable of hardening the cellular tissue itself of a solid cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue, is disclosed. The therapeutic agent for solid cancer is composed of a liquid composition containing as an active component an ethoxy-containing compound capable of undergoing polycondensation in a cellular tissue. The therapeutic agent for solid cancer is capable of hardening the cellular tissue itself of a solid cancer such as lung cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue. In conventional therapeutic methods, the risk of metastasis due to spreading of cancer cells through the bloodstream cannot be eliminated. In contrast, this therapeutic agent for solid cancer instantly surrounds cancer cells, so that the risk of metastasis can be largely reduced.

Abstract: An antibiotic polymethylmethacrylate bone cement that is composed of methylmethacrylate, at least one polymethylmethacrylate or a polymethylmethacrylate-copolymer, at least one polymerisation initiator, such as in radical initiator, at least one polymerisation accelerator, and at least one radiopaquer, whereby the components are present in a powdered component and a liquid monomer component or in two components that are pasty at room temperature. The polymethylmethacrylate bone cement comprises the cyclical lipopeptide, daptomycin, a pharmacologically tolerable salt of daptomycin, a solvate and/or a hydrate containing daptomycin and at least one calcium salt, which preferably comprises at least two different release profiles. The bone cement is useful in one-stage or two-stage septic revision surgery.

Abstract: The present invention relates to a material for preparing an intraocular lens. In particular, it relates to an ophthalmic medical material suitable for manufacture of micro-incision intraocular lens, having suitable water content and a suitable refractive index.

Abstract: A corneal implant includes one or more extracellular matrix (ECM) components; and one or more crosslinking/polymerization promoting agents, wherein the one or more ECM components undergo crosslinking/polymerization on exposure to an initiator.

Abstract: The present invention provides demineralized bone fibers exhibiting optimal handling properties (e.g., high moldability and low elastic modulus) and biological activities (e.g., osteoinductivity) as well as non-demineralized bone fibers useful for preparing the demineralized bone fibers. A well-controlled demineralization process for preparing the demineralized bone of fibers is also provided. Products comprising the demineralized bone fibers and uses thereof are further provided.

Abstract: A substitute composition is provided that includes at least one cadaveric material and at least one liquid component which, upon introduction to the cadaveric material, causes the cadaveric material to expand and become flowable. Methods for stabilizing a vertebral space are also provided.

Abstract: Tissue prostheses having a base structure and a physiological sensor system. The tissue prostheses are adapted and configured to induce remodeling of damaged tissue and regeneration of new tissue and concurrently detect and monitor physiological characteristics when implanted in the subject.

Abstract: Provided herein are meniscus implant compositions, as well as method for making and using the same. The subject meniscus implants find use in repairing and/or replacing damaged or diseased meniscal tissue in a mammalian subject.

Abstract: A biological material with composite extracellular matrix component, in which decellularized small intestinal submucosa (SIS) is treated as the interlayer and decellularized urinary bladder matrix (UBM) is treated as superior and inferior surface layers. The interlayer is totally encapsulated by the superior and inferior surface layers, forming a sandwich structure. The biological material integrates the advantages of UBM and SIS: {circle around (1)} High bioactivity with bionic structure; {circle around (2)} UBM isolates the immunogenicity of SIS and directly contacts host tissue; {circle around (3)} SIS can make up for the disadvantage of low mechanical strength of UBM, the preparation of SIS is easier, and its thickness is subject to change after composition; {circle around (4)} raw materials of same origin are feasible for industrial large-scale production.

Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.

Abstract: The present invention relates to the unexpected discovery of novel hydrogel formulations that allow for the encapsulation and delivery of living cells and/or drugs to a subject in need thereof. In certain embodiments, the hydrogel compositions of the invention comprise bound bioactive molecules that promote long-term cell viability and allows for the development of vasculature. The invention further provides methods of delivering viable cells and/or drugs to a subject comprising administering the compositions of the invention to the subject in need thereof.

Abstract: The present invention relates to a biopolymer-based hydrogel as a functional biomaterial produced by crosslinking in the presence of a photopolymerization initiator. The hydrogel of the present invention is elastic so as to be adapted to various shapes in both in vivo and in vitro applications. It is biocompatible, achieving maximum effects on wound healing as wound dressing and tissue adhesion preventing material. The present invention also relates to a method for producing the biocompatible hydrogel.

Abstract: A composite comprising: a barrier, said barrier being configured to selectively pass water, and said barrier being degradable in the presence of water; a matrix material for disposition within said barrier, wherein said matrix material has a flowable state and a set state, and wherein said matrix material is degradable in the presence of water; and at least one reinforcing element for disposition within said barrier and integration with said matrix material, wherein said at least one reinforcing element is degradable in the presence of water, and further wherein, upon the degradation of said at least one reinforcing element in the presence of water, provides an agent for modulating the degradation rate of said matrix material in the presence of water.

Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Abstract: A dissolvable composition is disclosed. The composition includes a first material (e.g., an anode), a second material (e.g., a cathode), and a third material (electrolytic material). The third material is reactive with water to form an electrolyte. The first material and the second material are electrochemically different such that the first material and the second material are capable of galvanic reaction in the presence of water and electrolytes. Also disclosed are tools or other apparatus made from the composition, as well as processes, systems, and apparatus for making and using such compositions, tools, and other apparatus.

Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a first component having a first substrate and a second component having a second substrate. The second component is positioned within the first component. One of the first and second substrates includes a hemostatic agent and the other of the first and second substrates includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

Abstract: A needle assembly includes an outer cannula having a distal end portion, the distal end portion comprising a sharp bevel facilitating insertion of the needle assembly into a subject. The needle assembly further includes an inner cannula slidably disposed coaxially in the lumen of the outer cannula and movable between an extended position and a retracted position, the inner cannula having a blunt distal end portion extending beyond the sharp bevel of the outer cannula whenever the inner cannula is in the extended position. The needle assembly further includes a bias coupled to the inner cannula in a manner favoring automatic positioning of the inner cannula at the extended position. The needle assembly includes a valve located in fluid communication with the lumen of the inner cannula to allow fluid to exit the subject through the inner cannula, and to prevent ingress of fluid into the subject.

Abstract: A system for improving a breastpumping session is disclosed. The system includes a database having at least one data group, the database being configured to send and receive group data regarding a pumping pattern. The system also includes at least one data processing unit configured to analyze pumping data regarding the breastpumping session and compare the pumping data to the group data. Further, the system includes at least one breast pump system communicably coupled to the data processing unit. Real-time changes to the breastpumping session are implemented to the breast pump system based on the analysis of the pumping data.

Abstract: Materials and methods related to blood pump systems are described. These can be used in patients to, for example, monitor arterial pressure, measure blood flow, maintain left ventricular pressure within a particular range, avoid left ventricular collapse, prevent fusion of the aortic valve in a subject having a blood pump, and provide a means to wean a patient from a blood pump.

Abstract: The present disclosure relates to an improved transcutaneous energy transfer (TET) system that generates and wirelessly transmits a sufficient amount of energy to power one or more implanted devices, including a heart pump, while maintaining the system's efficiency, safety, and overall convenience of use. The disclosure further relates one or more methods of operation for the improved system.

Abstract: A fluid handling cassette, such as that useable with an automated peritoneal dialysis (APD) cycler device or other infusion apparatus, may include a generally planar body having at least one pump chamber formed as a depression in a first side of the body and a plurality of flowpaths for a fluid that includes a channel. A patient line port may be arranged for connection to a patient line and be in fluid communication with the at least one pump chamber via at least a first one of said flowpaths, and an optional membrane may be attached to the first side of the body over the at least one pump chamber. In one embodiment, the membrane may have a pump chamber portion with an unstressed shape that generally conforms to the depression of the at least one pump chamber in the body and is arranged to be movable for movement of the fluid in a useable space of the at least one pump chamber.